Africa’s biggest generic drug maker Aspen Pharmacare, already under investigation by European authorities over the price of its cancer drugs, is now under similar scrutiny from SA’s Competition Commission.
On Tuesday, the commission announced it was investigating Aspen and multinational pharmaceutical manufacturers Roche and Pfizer for suspected excessive pricing of their cancer drugs.
If the Competition Commission’s investigation uncovers abuses, the matter will be referred to the Competition Tribunal for prosecution. The maximum penalty the tribunal can levy is 10% of annual turnover.